MedTrace Logo

Rosuvastatin on Diabetic Patients Treated With Glimepiride/Metformin

NCT03907423 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2023-04-14

No results posted yet for this study

Summary

study effects of rosuvastatin on markers of atherosclerosis, thrombosis, in diabetic patients treated with glimepiride/metformin without coronary artery disease.

This effect will be investigated especially on sortilin ,fetuin-A

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

Rosuvastatin10 mg tablet

Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral

DRUG

Placebo Oral Tablet

Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral

Sponsors & Collaborators

  • Rehab Werida

    lead OTHER

Principal Investigators

  • Rehab H Werida, Ass.Prof. · Damanhour University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2021-01-19
Completion
2021-01-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03907423 on ClinicalTrials.gov